A successful desensitization in an adult patient with ARA-C infusion reaction.

Autor:	Akgul Balaban Y; Division of Immunology and Allergic Diseases, Gulhane Training and Research Hospital, Ankara, Turkiye., Inan MI; Division of Immunology and Allergic Diseases, Gulhane Training and Research Hospital, Ankara, Turkiye., Selcuk A; Division of Immunology and Allergic Diseases, Gulhane Training and Research Hospital, Ankara, Turkiye., Kartal O; Division of Immunology and Allergic Diseases, Gulhane Training and Research Hospital, Ankara, Turkiye., Zengin H; Division of Hematology, Gulhane Training and Research Hospital, Ankara, Turkiye., Bulduk T; Division of Hematology, Gulhane Training and Research Hospital, Ankara, Turkiye.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Jun; Vol. 30 (4), pp. 780-782. Date of Electronic Publication: 2024 Mar 28.
DOI:	10.1177/10781552241242691
Abstrakt:	Introduction: Cytarabine (ARA-C) is an antimetabolite agent used especially in the treatment of hematologic malignancies. Infusion reactions have an important place among the side effects that may occur due to treatment. Clinical findings of infusion reactions resemble allergic reactions. Case Report: 47-year-old male patient with a diagnosis of B-cell Acute Lymphoblastic Leukaemia developed infusion reaction during ARA-C treatment. Management & Outcome: There was no alternative treatment option for his existing malignant disease, we decided ARA-C desensitization. Discussion: We would like to describe a successful desensitization protocol in an adult patient who experienced a reaction during ARA-C infusion. Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu